Published in Brain Pathol on March 26, 2008
Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells (2009) 2.10
Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res (2008) 1.58
Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med (2009) 1.48
Current strategies for identification of glioma stem cells: adequate or unsatisfactory? J Oncol (2012) 1.40
Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer (2010) 1.35
CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO J (2011) 1.32
Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer (2010) 1.31
The perivascular niche microenvironment in brain tumor progression. Cell Cycle (2010) 1.30
CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS One (2011) 1.23
Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem (2011) 1.14
Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro Oncol (2009) 1.10
Thyroid cancer stem cells. Nat Rev Endocrinol (2011) 1.07
Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci (2011) 1.03
CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma. BMC Cancer (2011) 1.02
What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Exp Pathol (2013) 1.02
Novel anti-apoptotic microRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim. PLoS One (2014) 1.01
Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. Gastric Cancer (2012) 0.98
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J Transl Med (2012) 0.97
Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms. J Cell Mol Med (2013) 0.95
TRPM7 channels regulate glioma stem cell through STAT3 and Notch signaling pathways. Cell Signal (2014) 0.94
Cancer stem cells and their role in metastasis. Pharmacol Ther (2013) 0.93
A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. PLoS One (2013) 0.93
Clinical value of CD133 and nestin in patients with glioma: a population-based study. Int J Clin Exp Pathol (2014) 0.92
Origins and clinical implications of the brain tumor stem cell hypothesis. J Neurooncol (2009) 0.92
CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. Acta Neuropathol (2012) 0.91
Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1. BMC Cancer (2012) 0.90
Establishment of prognostic models for astrocytic and oligodendroglial brain tumors with standardized quantification of marker gene expression and clinical variables. Biomark Insights (2010) 0.89
Carbon nanotubes in hyperthermia therapy. Adv Drug Deliv Rev (2013) 0.89
Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl Med (2012) 0.88
Evaluation of radiotherapy effect in resveratrol-treated medulloblastoma cancer stem-like cells. Childs Nerv Syst (2009) 0.88
Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol Cancer Res (2010) 0.88
Medulloblastoma-derived tumor stem-like cells acquired resistance to TRAIL-induced apoptosis and radiosensitivity. Childs Nerv Syst (2010) 0.86
Cancer stem cells - the current status of an old concept: literature review and clinical approaches. Biol Res (2014) 0.85
Prognostic value of glioma cancer stem cell isolation in survival of primary glioblastoma patients. Stem Cells Int (2014) 0.85
Malignant clinical features of anaplastic gliomas without IDH mutation. Neuro Oncol (2014) 0.83
Identification of CD133(-)/telomerase(low) progenitor cells in glioblastoma-derived cancer stem cell lines. Cell Mol Neurobiol (2010) 0.83
Stemness of the CT-2A Immunocompetent Mouse Brain Tumor Model: Characterization In Vitro. J Cancer (2012) 0.80
Unique case of oligoastrocytoma with recurrence and grade progression: Exhibiting differential expression of high mobility group-A1 and human telomerase reverse transcriptase. World J Clin Cases (2016) 0.79
Oligodendrocyte/type-2 astrocyte progenitor cells and glial-restricted precursor cells generate different tumor phenotypes in response to the identical oncogenes. J Neurosci (2013) 0.78
A novel fixative for immunofluorescence staining of CD133-positive glioblastoma stem cells. J Neurosci Methods (2011) 0.77
MicroRNA-203 As a Stemness Inhibitor of Glioblastoma Stem Cells. Mol Cells (2016) 0.77
Targeting tumor metastases: Drug delivery mechanisms and technologies. J Control Release (2015) 0.76
Differential proliferative index of cancer stem-like cells in primary and recurrent medulloblastoma in human. Childs Nerv Syst (2012) 0.76
Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas. J Neurooncol (2016) 0.76
The cellular senescence of leukemia-initiating cells from acute lymphoblastic leukemia is postponed by β-Arrestin1 binding with P300-Sp1 to regulate hTERT transcription. Cell Death Dis (2017) 0.75
Detection of CD133 expression in U87 glioblastoma cells using a novel anti-CD133 monoclonal antibody. Oncol Lett (2015) 0.75
PNIPAAm-co-Jeffamine(®) (PNJ) scaffolds as in vitro models for niche enrichment of glioblastoma stem-like cells. Biomaterials (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Neuroplasticity: changes in grey matter induced by training. Nature (2004) 7.35
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res (2007) 6.21
Doublecortin expression levels in adult brain reflect neurogenesis. Eur J Neurosci (2005) 3.79
Sodium fluorescein-guided resection under the YELLOW 560 nm surgical microscope filter in malignant brain tumor surgery--a feasibility study. Acta Neurochir (Wien) (2013) 3.41
Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res (2008) 2.84
Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol (2012) 2.59
Effects of the implementation of a telemedical stroke network: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria, Germany. Lancet Neurol (2006) 2.38
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res (2004) 2.35
Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol (2009) 2.22
Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem (2004) 2.17
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem (2006) 2.08
The variability of atlas-based targets in relation to surrounding major fibre tracts in thalamic deep brain stimulation. Acta Neurochir (Wien) (2014) 2.04
Awake craniotomies without any sedation: the awake-awake-awake technique. Acta Neurochir (Wien) (2013) 2.02
Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol (2007) 2.02
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol (2010) 1.87
RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res (2004) 1.83
Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res (2010) 1.76
Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol (2006) 1.70
General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. Cancer Res (2010) 1.64
Aberrant Wnt/beta-catenin signaling can induce chromosomal instability in colon cancer. Proc Natl Acad Sci U S A (2006) 1.64
Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Mol Cancer (2011) 1.64
No association between MUTYH and MSH6 germline mutations in 64 HNPCC patients. Eur J Hum Genet (2008) 1.58
A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem (2011) 1.58
Fluorescein sodium-guided resection of cerebral metastases—experience with the first 30 patients. Acta Neurochir (Wien) (2015) 1.55
TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain (2006) 1.54
Prevalence of the mismatch-repair-deficient phenotype in colonic adenomas arising in HNPCC patients: results of a 5-year follow-up study. Int J Colorectal Dis (2006) 1.54
Preoperative evaluation of carotid artery stenosis: comparison of contrast-enhanced MR angiography and duplex sonography with digital subtraction angiography. AJNR Am J Neuroradiol (2003) 1.46
Transforming growth factor-beta1 is a negative modulator of adult neurogenesis. J Neuropathol Exp Neurol (2006) 1.44
Intracranial hemorrhage: frequency, location, and risk factors identified in a TeleStroke network. Neuroreport (2015) 1.42
A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol (2002) 1.41
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides (2007) 1.40
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet (2012) 1.40
In vivo optical imaging of neurogenesis: watching new neurons in the intact brain. Mol Imaging (2008) 1.34
Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res (2007) 1.33
Long-term effects of specialized stroke care with telemedicine support in community hospitals on behalf of the Telemedical Project for Integrative Stroke Care (TEMPiS). Stroke (2008) 1.33
CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO J (2011) 1.32
Different types of microsatellite instability in ovarian carcinoma. Int J Cancer (2004) 1.30
The promotion of oriented axonal regrowth in the injured spinal cord by alginate-based anisotropic capillary hydrogels. Biomaterials (2006) 1.30
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther (2007) 1.29
Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis (2006) 1.29
Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro Oncol (2008) 1.27
Targeted transgene expression in neuronal precursors: watching young neurons in the old brain. Eur J Neurosci (2006) 1.26
Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. J Pathol (2004) 1.26
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging (2014) 1.26
Further evidence for heritability of an epimutation in one of 12 cases with MLH1 promoter methylation in blood cells clinically displaying HNPCC. Eur J Hum Genet (2008) 1.25
Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J (2006) 1.25
Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol (2009) 1.24
Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol (2008) 1.23
Cerebral ischemia-reperfusion injury in rats--a 3 T MRI study on biphasic blood-brain barrier opening and the dynamics of edema formation. J Cereb Blood Flow Metab (2009) 1.23
Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb. Exp Neurol (2005) 1.22
Mutant alpha-synuclein exacerbates age-related decrease of neurogenesis. Neurobiol Aging (2007) 1.22
GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res (2010) 1.20
Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res (2002) 1.20
Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res (2009) 1.19
Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer (2004) 1.19
Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev (2005) 1.19
When should conservative treatment for lumbar disc herniation be ceased and surgery considered? Neurosurg Rev (2002) 1.18
Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells. Stem Cells (2006) 1.14
High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS One (2011) 1.11
Can telemedicine contribute to fulfill WHO Helsingborg Declaration of specialized stroke care? Cerebrovasc Dis (2005) 1.11
Salvage therapy in patients with glioblastoma: is there any benefit? Cancer (2003) 1.11
The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle (2007) 1.11
Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer (2006) 1.11
Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol (2007) 1.10
Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke (2011) 1.09
Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother (2011) 1.09
A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One (2012) 1.09
The usefulness of the awake-awake-awake technique. Acta Neurochir (Wien) (2014) 1.08
Long-term course and mutational spectrum of spatacsin-linked spastic paraplegia. Ann Neurol (2007) 1.08
Letter by Schlachetzki et al regarding article, "endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome". Stroke (2013) 1.07
Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions. Am J Surg Pathol (2009) 1.07
TGF-beta in neural stem cells and in tumors of the central nervous system. Cell Tissue Res (2007) 1.06